COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS, LLC) for COMPLETE PHARMA HOLDINGS LLC (CP) (FORMERLY: MARATHON PHARMACEUTICALS LLC)
What was lobbied
9 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Budget/Appropriations BUD
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Pharmacy PHA
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Medical/Disease Research/Clinical Labs MED
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Science/Technology SCI
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Trade (domestic/foreign) TRD
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Taxation/Internal Revenue Code TAX
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Health Issues HCR
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Government Issues GOV
FDA Regulatory Issues Pharmaceutical Access Issues Rare Disease Drug Development Issues Duchenne Muscular Dystrophy Funding and Pharmaceutical Pricing
| Lobbyist | Covered position, as disclosed |
|---|---|
| GREGORY ARONIN New | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.